Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GlucoTrack, Inc. (NASDAQ: GCTK) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a smaller reporting company and Nasdaq-listed medical device issuer, GlucoTrack uses these filings to disclose information about its implantable Continuous Blood Glucose Monitor (CBGM) program, financial condition, capital structure, and corporate governance.
Through this page, readers can review current reports on Form 8‑K, where GlucoTrack reports material events such as clinical and financial press releases, special stockholder meetings, financing agreements, and warrant repurchases. Registration statements like Form S‑1 detail equity purchase arrangements and potential resales of common stock tied to committed equity facilities, while proxy materials such as DEF 14A describe stockholder proposals related to share issuances and special meetings.
Annual and quarterly reports (Forms 10‑K and 10‑Q, referenced in company communications) contain management’s discussion and analysis of operating results, descriptions of the CBGM development program, and risk factors that include the need for additional capital, clinical and regulatory uncertainties, and other considerations typical for an investigational medical device company. These filings also outline GlucoTrack’s status as a smaller reporting company and its listing on the Nasdaq Capital Market under the symbol GCTK.
On Stock Titan, GlucoTrack filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as equity line terms, private placements, warrant transactions, and clinical disclosure language. Real-time updates from EDGAR, along with structured access to current reports, registration statements, and proxy materials, allow investors and researchers to follow how GlucoTrack describes the evolution of its implantable CBGM platform, financing strategy, and corporate actions in its official SEC record.
Glucotrack, Inc. outlined clinical and operational progress that supports its plan to submit an Investigational Device Exemption (IDE) to the FDA for its implantable continuous blood glucose monitoring (CBGM) system in Q2 2026, aiming to start a U.S. clinical trial in the second half of 2026, subject to FDA approval.
The company completed a 5‑day first‑in‑human study in Brazil with 10 participants, achieving a Mean Absolute Relative Difference of 7.7% across 122 matched pairs, 99% data capture, and no procedure or device‑related serious adverse events. A follow‑on feasibility trial in Australia produced similar performance and informed protocol and product refinements.
Glucotrack also secured a U.S. trial site, engaged a CRO experienced in diabetes medtech, and completed targeted design iterations. In 2025 it was awarded three U.S. patents (US 12,453,494; US 12,458,257; US 12,458,258) covering sensor chemistry, intravascular lead design, and low‑power electronics for its three‑year longevity CBGM platform.
Glucotrack, Inc. held a special shareholder meeting where investors approved several key proposals related to future stock issuances and auditor ratification. As of the January 28, 2026 record date, 1,011,279 common shares were outstanding, and 446,348 votes (about 44.1%) were represented, forming a quorum.
Shareholders approved a Nasdaq Stock Issuance (ELOC) Proposal authorizing the full issuance of shares of common stock to Sixth Borough Capital Fund, LP under a September 11, 2025 purchase agreement, which may exceed 20% of shares outstanding on that date. They also approved the Nasdaq Stock Issuance (Warrants) Proposal for the full issuance of shares underlying 2,067,182 common warrants from a December 31, 2025 private placement, with 26,134 votes for and 18,151 against after excluding 100,591 ineligible shares.
In addition, shareholders ratified the appointment of CBIZ CPAs P.C. as independent auditor for the year ended December 31, 2025, with 431,871 votes in favor. An adjournment proposal was not needed because all principal proposals received sufficient support.
Glucotrack, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 101,075 common shares, representing 9.99% of the class as of 12/31/2025.
The filing states the shares are held with shared voting and dispositive power of 101,075. The Master Fund, a Cayman Islands client of Armistice Capital, has the right to receive dividends or sale proceeds for these securities. Signatures date the filing 02/17/2026.
Ikarian Capital, LLC and Neil Shahrestani reported beneficial ownership of 45,830 shares of Glucotrack, Inc. (GCTK) common stock, representing 4.5% of the class. This percentage is based on 1,011,279 shares outstanding as of January 28, 2026, as disclosed in Glucotrack’s definitive proxy statement.
The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Glucotrack.
Glucotrack, Inc. is calling a virtual special stockholder meeting on March 12, 2026 to approve several key capital and governance items. The main proposals seek approval under Nasdaq Listing Rule 5635(d) for two highly dilutive stock issuances: up to $20.0 million of common stock to Sixth Borough Capital Fund via an equity line purchase agreement, and the full issuance of common shares underlying 2,067,182 common warrants sold in a December 2025 private placement with Armistice Capital Master Fund.
On the January 28, 2026 record date, Glucotrack had 1,011,279 shares outstanding. If all pre-funded and common warrants from the private placement are exercised and held, Armistice could own about 3,100,773 shares, or roughly 77.29% of the then-outstanding common stock, significantly diluting existing holders. The proxy explains Nasdaq’s 20% issuance limits and why stockholder approval is needed to exceed them.
Management states that failure to approve the warrant-related issuance could cut off up to roughly $8 million of potential cash from warrant exercises and may jeopardize Glucotrack’s ability to fund its business, potentially forcing liquidation or bankruptcy protection. Stockholders are also asked to ratify CBIZ CPAs P.C. as auditor for 2025, following the 2025 dismissal of Grant Thornton, whose prior reports included going concern language and identified material weaknesses in internal controls. A final proposal would allow adjournment of the meeting to solicit additional proxies if needed. The Board unanimously recommends voting “FOR” all four proposals.
Glucotrack, Inc. is calling a special shareholder meeting on March 12, 2026 to approve several key proposals tied to its financing plans and auditor appointment. Shareholders will vote on authorizing full share issuances under a $20 million equity line with Sixth Borough Capital and on issuing shares for 2,067,182 common warrants sold in a December 31, 2025 private placement.
As of January 28, 2026, Glucotrack had 1,011,279 common shares outstanding. If all pre-funded and common warrants from the private placement are exercised, the investor could hold about 3,100,773 shares, or 77.29% of the then-outstanding stock, significantly diluting other holders. The company notes that failure to approve the warrant issuance could prevent it from accessing up to roughly $8 million of potential proceeds and may jeopardize its ability to fund operations, potentially forcing liquidation or bankruptcy.
Shareholders will also vote on ratifying CBIZ as independent auditor for 2025 and on allowing adjournment of the meeting to solicit additional proxies if needed. The board unanimously recommends voting in favor of all four proposals.
Glucotrack, Inc. filed a current report to furnish a press release dated January 29, 2026 under Regulation FD. The company attached the press release as Exhibit 99.1 to provide investors with the same information shared publicly. No financial results or major transactions are described in this excerpt.
Glucotrack, Inc. has registered up to 3,224,803 shares of common stock for resale by existing investors, all issuable from pre-funded, common, and placement agent warrants issued in a December 2025 private placement.
The company will not receive any proceeds from these resale transactions; it previously received approximately $4.0 million in gross proceeds when the warrants were originally sold. As of January 12, 2026, only 910,688 shares of common stock were outstanding, so the registered shares equal about 354% of current shares, creating a large potential overhang that the company warns could significantly pressure its stock price.
Glucotrack is a clinical-stage company developing a fully implantable continuous blood glucose monitor and has reported promising early human data, but it has a long history of losses, substantial doubt about its ability to continue as a going concern, and a challenging Nasdaq listing history that has required multiple reverse stock splits to maintain compliance.
Glucotrack, Inc. is registering 3,224,803 shares of common stock for resale by warrant holders from a December 2025 private placement. The shares consist of 1,033,591 shares underlying pre-funded warrants with a $0.001 exercise price, 2,067,182 shares underlying common warrants with a $3.87 exercise price, and 124,030 shares underlying placement agent warrants with a $4.257 exercise price. Glucotrack will not sell shares or receive proceeds from these resales.
The registered shares equal about 354% of the 910,688 shares outstanding as of January 12, 2026, creating significant potential dilution and stock overhang. The company is a smaller reporting company developing a fully implantable continuous blood glucose monitor and has reported promising first-in-human accuracy data but also substantial historical losses, going concern doubts, and a history of Nasdaq listing compliance issues.